Search

Search Constraints

You searched for: Author/Creator Migkou, Magdalini

Search Results

1. B03: SKELETAL-RELATED EVENTS AND ABNORMAL MRI PATTERN AT DIAGNOSIS ARE ASSOCIATED WITH INFERIOR OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA. (5th April 2022)

2. Bone marrow biopsy in low‐risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. Issue 5 (6th March 2019)

3. Bortezomib‐based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. Issue 5 (4th April 2016)

4. Cell‐free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations. Issue 6 (15th April 2020)

5. Chromosome 1q21 aberrations identify ultra high‐risk myeloma with prognostic and clinical implications. Issue 9 (29th June 2022)

6. Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: Prognostic and More. Issue 3 (30th September 2022)

7. Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases. Issue 4 (3rd April 2018)

8. Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates. Issue 4 (10th January 2019)

9. Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease. (2nd October 2021)

10. Daratumumab‐based therapy for patients with monoclonal gammopathy of renal significance. (23rd August 2020)